Dr. Mehak Zahoor Khan

Translating fundamental discoveries into therapeutic innovation.
Bacterial Immunologist with 12+ years research experience advancing vaccine development, systems immunology, and functional antibody therapeutics at premier institutions and industry leaders.

About Me

Dr. Mehak Zahoor Khan

I am a bacterial immunologist and vaccine development scientist dedicated to bridging fundamental research and therapeutic innovation. My career spans translational immunology at world-class institutions—from the Ragon Institute of MGH, MIT and Harvard and the National Institute of Immunology in India to top innovative biotech including Moderna Therapeutics and Omniose.

My research focuses on understanding protective immunity against infectious diseases and translating those insights into next-generation vaccines and antibody therapeutics. I combine systems serology, functional immunology, and multi-omic approaches to define disease mechanisms and enable rational therapeutic design.

Current role: Scientist III (Principal Scientist equivalent) at Omniose, leading functional immunology for bacterial vaccine development and NIH-supported programs targeting critical global health pathogens.

Expertise: Monoclonal Antibody Discovery · Antibody Engineering · Vaccine Development · Systems Serology · Functional Immunoassays · Translational Research · Program Management · Scientific Leadership

Impact Metrics

589
Citations to date
19
Peer-reviewed publications
1
Book chapter
2
Editorials
8
First/co-first authored
1
Invention disclosure
2
Editorial board positions
50+
Peer reviews completed
Career Timeline ▼

Scientist III (Principal Scientist equivalent)

Omniose, St. Louis, MO
April 2026 - Present
  • Lead assay development and standardization for preclinical vaccines and biologics, enabling robust, reproducible measurement of functional antibody-mediated protection.
  • Optimized high-throughput opsonophagocytic killing and serum bactericidal assays across three preclinical programs, reducing manual processing time by 50% and driving substantial cost savings.
  • Integrate functional immunological readouts with serological profiling to inform candidate selection and translational go/no-go decision-making.
  • Liaise across internal and external stakeholders, maintaining communication pathways, timelines, and regularly presenting on project progress to leadership.
  • Prepare technical summaries, protocols, quantitative analyses, and maintain comprehensive documentation.

Senior Research Fellow

Ragon Institute of Mass General Brigham, MIT and Harvard, Cambridge, MA
January 2025 - March 2026
  • Isolated and Fc-engineered high affinity antibodies against S. aureus and Shigella targets through single B cell screening technologies followed by NGS.
  • Led a translational immunology program that generated a high-dimensional systems serology dataset comprising 182,149 antibody features from pediatric Staphylococcus aureus infections, enabling discovery of protective humoral signatures for vaccine and monoclonal antibody development.
  • Defined mucosal and systemic correlates of protection against Bordetella pertussis, uncovering functional IgG/IgA signatures that inform next-generation pertussis vaccines.
  • Conducted a multi-omic investigation integrating systems serology, digital spatial transcriptomics, single-nucleus RNA-seq, proteomics, and biophysical modeling to define humoral immune mechanisms underlying long-term survival in pancreatic ductal adenocarcinoma (PDAC).
  • Profiled maternal–infant Shigella cohorts, discovering protective humoral responses in maternal serum and breast milk guiding maternal immunization approaches.
  • Mentored and oversaw day-to-day operations of junior research fellows, research technicians, and interns (up to 3 direct reports).

Senior Scientist, Immunology (Infectious Diseases)

Moderna Therapeutics, Cambridge, MA
November 2022 - January 2025
  • Advanced bacterial antibody discovery programs from concept to preclinical stage, focusing on the development of therapeutic candidates, optimizing immunization strategies, and utilizing B cell separation and plasma/memory B cell sorting techniques including FACS.
  • Engineered antibodies to improve potency, affinity, half-life, and developability.
  • Served as scientific research lead for two global health mRNA vaccine programs, driving key decisions including vaccine antigen selection, experimental strategy, assay development, immune profiling, data interpretation, and cross-functional decision-making to support antigen prioritization and candidate advancement.
  • Applied PhIP-Seq for high-throughput antigen identification and antibody profiling, enabling discovery of protective and therapeutic candidates.
  • Supervised associates and coordinated multi-site collaborations with KOLs and external partners.

Postdoctoral Research Associate

Ragon Institute of Mass General Brigham, MIT and Harvard, Cambridge, MA, USA & National Institute of Immunology, India
January 2020 - November 2022
  • Generated a proteome-wide atlas of protective humoral immunity to M. tuberculosis across the disease spectrum.
  • Investigated vaccine-mediated protective response against respiratory syncytial virus.
  • Identified immune regulatory mechanisms by which antibodies leverage control of M. tuberculosis.
  • Demonstrated that Fc-engineered antibodies enhance neutrophil-mediated killing of M. tuberculosis, providing proof-of-concept for antibody engineering as a host-directed therapy.
  • Unraveled host–pathogen mechanisms in M. tuberculosis, including kinase regulation of latency and oxidative stress pathways.
  • Identified host Sirtuin-2 as an immunotherapeutic target against tuberculosis, establishing a new host-directed intervention strategy.

PhD in Microbiology

National Institute of Immunology, New Delhi, India
June 2014 - January 2020
  • Discovered novel transcriptional and signaling pathways regulating M. tuberculosis persistence and virulence, contributing to 14+ high-impact publications.
Research Contributions ▼

Advancing understanding of protective immunity and translating discoveries into therapeutic solutions

mAb Discovery

Successfully led monoclonal antibody and nanobody discovery campaigns for at least six bacterial targets from human PBMCs and immunized animals.

Fc-Engineered Antibody Therapeutics

Advanced antibody engineering for enhanced potency, affinity, half-life, developability and immune effector functions. Extended approach across S. aureus, Shigella, RSV, SARS-CoV-2, and cancer targets.

mRNA Vaccine Development

Led antigen selection and immune profiling for TB and Malaria vaccines. Demonstrated preclinical efficacy of multivalent mRNA candidates surpassing current BCG vaccine performance.

Systems Serology & Immune Profiling

Generated high-dimensional antibody datasets (182K+ features) across multiple pathogens. Defined protective humoral signatures enabling rational vaccine design and patient stratification approaches.

Biomarker Assay Innovation

Optimized opsonophagocytic killing, serum bactericidal, ADCP, ADNP, ADCD assays. Reduced manual processing by 50%. Standardized functional readouts for vaccine and therapeutic evaluation.

Multi-omic Integration

Synthesized systems serology, spatial transcriptomics, RNA-seq, and proteomics. Identified antibody-mediated disease mechanisms in cancer. Designed innovative therapeutic strategies.

Awards & Recognition ▼

National and international recognition for scientific excellence (most recent first)

2026
Distinguished Alumni Award
Institute of Home Economics, University of Delhi
2026
Sigma Xi Full Membership
Scientific Research Honor Society
2023
INSA Young Scientist Medal
Indian National Science Academy
2022
Research Excellence Award
India Investigator Network
2020
DST-INSPIRE Faculty Award
Government of India
2019
Global Health Travel Award
Bill & Melinda Gates Foundation
2018
Best Poster Award by JBC
India-EMBO TB Symposium
2017
Best Poster Award
NII Young Emerging Scientist Symposium
2014
University Gold Medal
University of Delhi (Academic Excellence)
2014
Monsanto Scholarship
Academic Excellence, University of Delhi
2014
Research Fellowship
University Grants Commission, Government of India
2014
Valedictorian
University of Delhi (M.Sc. & B.Sc.)
2014
AIR-131
Graduate Aptitude Test in Engineering
2013
South Campus Endowment Scholarship
Academic Excellence, University of Delhi
2012
Dr. Kumud Khanna Award
Best Student in Biochemistry, University of Delhi
2012
Teaching Staff Trophy
Best All-Round Student, University of Delhi
2012
Miss Summer Fields School Winner
Farewell Competition
Core Competencies ▼

Technical expertise and professional capabilities

Antibody Discovery & Engineering

  • Monoclonal antibody development
  • Nanobody discovery
  • Fc-engineering for enhanced developability and function
  • Affinity maturation
  • Antibody characterization

Vaccine Development

  • Antigen selection & optimization
  • mRNA, subunit and glycoconjugate vaccine design
  • Immunogenicity assessment
  • Candidate prioritization

Immunology & Serology

  • Functional immunoassays (OPK, ADCP, SBA, ADNP, ADCD)
  • Systems serology & immune profiling
  • ELISA, multiplex Luminex, Octet/BLI

Molecular Biology

  • Bacterial microbiology & genetics
  • Cell culture & primary immune cells
  • Flow cytometry & cell sorting
  • In vivo infection models

Data & Computational

  • R & Python programming
  • High-dimensional data analysis
  • NGS analysis & interpretation
  • Multi-omic data integration

Leadership & Strategy

  • Scientific program direction
  • Cross-functional team leadership
  • CRO & vendor collaboration
  • Grant writing & patents

Publications

Peer-reviewed research in high-impact journals (most recent first) | click titles to read full publications

🔵 First/Co-First Authored
A proteome-wide atlas of humoral immunity to Mycobacterium tuberculosis across the spectrum of disease
Khan MZ*, Irvine EB*, Cizmeci D*, ...Alter G. CO-FIRST
Frontiers in Immunology (2026)
Systemic and Mucosal Antibody Correlates of Protection Against Bordetella pertussis in a Controlled Human Infection Model
Khan MZ*, Kapoor Y*, Kliuchnikov E*, et al. CO-FIRST
MedRxiv (2026) | Preprint
Antibody Correlates of Resilience to Staphylococcus aureus Disease and Recurrence in Children
Khan MZ*, Kao CM*, Jung W, et al. CO-FIRST
BioRxiv (2026) | Preprint
Divergent downstream biosynthetic pathways are supported by L-cysteine synthases of M. tuberculosis
Khan MZ, Hunt B, Singha B, Kapoor Y, Singh NK, et al. FIRST AUTHOR
eLife (2024)
Deletion of pknG abates reactivation of latent Mycobacterium tuberculosis in mice
Khan MZ and Nandicoori VK. FIRST AUTHOR
Antimicrobial Agents and Chemotherapy (2021)
Redox homeostasis in Mycobacterium tuberculosis is modulated by a novel actinomycetes-specific transcription factor
Khan MZ, Singha B, Ali F, Khusman T, Rapole S, et al. FIRST AUTHOR
EMBO Journal (2021)
Protein kinase G confers survival advantage to Mycobacterium tuberculosis during latency-like conditions
Khan MZ*, Bhaskar A*, Upadhyay S*, et al. CO-FIRST
Journal of Biological Chemistry (2017)
⚪ Contributing Author
Fc-engineered antibodies enhance protection against SARS-CoV-2 lung infection and inflammation
Mackin SR, Liang C, Karl CE, et al., Khan MZ, et al.
mBio (2026)
Fc-engineered antibodies promote neutrophil-dependent control of Mycobacterium tuberculosis
Irvine EB*, Nikolov A, Khan MZ*, et al.
Nature Microbiology (2024) | 9:2369–2382
The unique N-terminal region of Mycobacterium tuberculosis sigma factor A plays a dominant role in the essential function of this protein
Singha B, Behera D, Khan MZ, et al.
Journal of Biological Chemistry (2023) | 299(3):102933
Host Sirtuin 2 as an immunotherapeutic target against tuberculosis
Bhaskar A, Kumar S, Khan MZ, et al.
eLife (2020) | e55415
Hydrophobicity of Cholic Acid-Derived Amphiphiles Dictates the Antimicrobial Specificity
Gupta S, Arora A, Khan MZ, et al.
ACS Biomaterials Science & Engineering (2022) | 8(11):4996–5007
Development of a Highly Specific, Selective, and Sensitive Fluorescent Probe for Detection of Mycobacteria in Human Tissues
Gupta S, Mishra DK, Khan MZ, Saini V, et al.
Advanced Healthcare Materials (2022) | e2102640
Interaction of mycobacterial protein PPE2 with p67phox prevents NADPH oxidase mediated ROS generation in macrophages
Srivasta S, Battu MB, Khan MZ, Nandicoori VK, Mukhopadhyay S.
Journal of Immunology (2019) | 203(5):1218-1229
Delineating FtsQ mediated regulation of cell division process in Mycobacterium tuberculosis
Jain P, Malakar B, Khan MZ, Lochab S, et al.
Journal of Biological Chemistry (2018) | 293(32):12331-12349
Genome-wide non-CpG methylation of the host genome during M. tuberculosis infection
Sharma G, Sowpati DT, Singh P, Khan MZ, et al.
Scientific Reports (2016) | 6:25006
📕 Book Chapter
Antibodies in COVID-19
Khan MZ, Leeson R, Henry C, Alter G.
In: Haseltine, The COVID-19 Textbook: Science, Medicine, and Public Health.
✍️ Editorial
Host-Pathogen Interactions in Intracellular Bacteria: Mechanisms, Evasion Strategies, and Therapeutic Insights
Khan MZ, Singh A, Khan J, Umar D, Hakeim O.
Frontiers in Molecular Bioscience (2026)

News & Media Coverage

Featured in leading science publications and media outlets

BioVoice News
Scientists find protein role in TB bacteria growth
BioVoice News
India BioScience
The ongoing chase: Tracking Mycobacterium tuberculosis in the evolutionary race
India BioScience
Scroll.in
Lab notes: Only optimal levels of a cell division protein allows the tuberculosis pathogen to grow
Scroll.in
SciSoup
Newer Insights Into An Age Old Bacteria
SciSoup
BioPatrika
Understanding how Mycobacterium tuberculosis tackles oxidative stress in the host
BioPatrika Researcher Spotlight
The Hindu
Researchers zero in on how the TB bacteria evade immune response
The Hindu
The Hindu Business Line
Scientists find protein role in TB bacteria growth
The Hindu Business Line

Posters & Invited Talks

Conference presentations and speaking engagements

Ragon Institute Scientific Seminars
Invited Speaker
Cambridge, Massachusetts, USA (2026)
Infectious Disease Research Day
Presenter
Moderna, Cambridge, Massachusetts, USA (2024)
Indian Investigator Network
Invited Speaker
India (2022)
India-EMBO TB Symposium: Mycobacterial Heterogeneity & Host Tissue Tropism
Presenter
New Delhi, India (2020)
🏆 Best Poster Award
Keystone A3: Tuberculosis - Mechanisms, Pathogenesis and Treatment
Poster Presentation
Banff, Canada (2019)
Young Emerging Scientist Symposium
Presenter
National Institute of Immunology, New Delhi, India (2017)
🏆 Best Poster Award
5th Global Forum for TB Vaccines
Presenter
New Delhi, India (2018)

Contact & Connect

Collaborate on vaccine development, translational immunology, and infectious disease research

LinkedIn

Connect

ResearchGate

Profile

Google Scholar

Profile